You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Allergies and anaphylaxis

Omalizumab for treating severe persistent allergic asthma

  • Technology appraisal guidance
  • Reference number: TA278
  • Published:  24 April 2013
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Information for the public

  • Omalizumab for severe persistent allergic asthma (PDF 165 KB)

    Published:
    24 April 2013
  • Gwybodaeth i'r cyhoedd (Word 275 KB)

    Published:
    07 October 2013